Viatris Inc
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $3.80B | $-0.10 | $0.69 |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $3.52B | $0.15 | $0.59 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $3.70B | $-0.30 | $0.57 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $3.76B | $-0.11 | $0.67 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $3.25B | $-2.55 | $0.50 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $3.53B | $-0.43 | $0.54 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $3.75B | $0.08 | $0.75 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | $3.80B | $-0.27 | $0.69 |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 28, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | 2026 | $4.30B to $4.50B | Raised |
| Adjusted EPSnon-GAAP | 2026 | $2.45 to $2.59 | Raised |
| Free Cash Flow Excluding Transaction-related and Restructuring-related Costsnon-GAAP | 2026 | $2.05B to $2.35B | Raised |
| U.S. GAAP net cash provided by operating activitiesGAAP | 2026 | $1.90B to $2.10B | Raised |
| Total RevenuesGAAP | 2026 | $14.55B to $14.95B | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Viatris filed with the SEC
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader
Material agreement · Other events · EX-99.1 to Form 8-K
Viatris Reports Second-Quarter 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports First-Quarter 2026 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Announces Chief Financial Officer Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Announces Appointment of David Simmons to the Company's Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Announces Appointments of Frank D’Amelio and Michael Severino, M.D., to the Company’s Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports Third Quarter Financial Results for 2024
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Announces Cash Tender Offers for Certain Outstanding Notes 1
Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Second Quarter Financial Results for 2024
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora Doretta Mistras
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Robert J. Coury Remarks at the 2023 Viatris Annual Meeting of Shareholders
Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Strong Financial and Operational Results for the Third Quarter 2023 and Reaffirms Full-Year 2023 Adjusted EBITDA and Free Cash Flow Guidance Ranges [1]
Results of operations · Other events · EX-99.1 to Form 8-K
Rajiv Malik to retire as President of Viatris effective April 1, 2024
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Announces Agreements on Remaining Planned Divestitures; Upon Closing Would Achieve its Original
Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and
Results of operations · Other events · EX-99.1 to Form 8-K
Robert J. Coury to Transition from Executive Chairman of Viatris to Chairman Emeritus and Senior
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Announces Appointment of Leo Groothuis to
Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Completes Biosimilars Transaction with Biocon Biologics
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans
Regulation FD disclosure · EX-99.1 to Form 8-K
Script of Viatris’ Executive Chairman’s “State of the Union” message from the conference call and live webcast held at 8:30am November
Regulation FD disclosure · EX-99.2 to Form 8-K
Viatris Reports Strong Third Quarter 2022 Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports Strong Second Quarter 2022 Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports Strong First-Quarter 2022 Results
Results of operations · Other events · EX-99.1 to Form 8-K
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results and Issues 2022 Financial Guidance
Results of operations · Other events · EX-99.1 to Form 8-K